Middle east respiratory syndrome coronavirus immunogens, antibodies, and their use

An isolated monoclonal antibody comprising a heavy chain variable region and a light chain variable region, comprising a heavy chain complementarity determining region (HCDR)1, a HCDR2, and a HCDR3, and a light chain complementarity determining region (LCDR)1, a LCDR2, and a LCDR3, of the VH and VL set forth as one of:

• (a) SEQ ID NOs:
• 2 and 4, respectively (JC57-13);
• (b) SEQ ID NOs:
• 6 and 8, respectively (JC57-11);
• (c) SEQ ID NOs:
• 10 and 12, respectively (JC57-14);
• (d) SEQ ID NOs:
• 36 and 38, respectively (C2);
• (e) SEQ ID NOs:
• 40 and 42, respectively (C5);
• (f) SEQ ID NOs:
• 44 and 46, respectively (A2);
• (g) SEQ ID NOs:
• 48 and 50, respectively (A10);
• (h) SEQ ID NOs:
• 52 and 54, respectively (FIB_B2);
• (i) SEQ ID NOs:
• 56 and 58, respectively (FIB_H1);
• (j) SEQ ID NOs:
• 36 and 110, respectively (C2 LCDR1 NG-NS);
• (k) SEQ ID NOs:
• 36 and 111, respectively (C2 LCDR1 NG-NA);
• (l) SEQ ID NOs:
• 115 and 117, respectively (G2);
• (m) SEQ ID NOs:
• 119 and 121, respectively (G4);
• (n) SEQ ID NOs:
• 123 and 125, respectively (D12);
• or
• (o) SEQ ID NOs:
• 127 and 129, respectively (F11);
• and
• wherein the monoclonal antibody specifically binds to MERS-CoV S protein.